Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581425 · ClinicalTrials.gov registry record · Phase 4
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
A Phase 4 study of Basal Cell Carcinoma, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT00581425: Completed Phase 4 study of Basal Cell Carcinoma, sponsored by The University of Texas Health Science Center, Houston.
NCT00581425 is a Phase 4 study of Basal Cell Carcinoma that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 49 participants, below the 102-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00581425, a Phase 4 study of Basal Cell Carcinoma, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
Conditions Studied
Interventions
- BIOLOGICAL Imiquimod and Interferon alpha
Study Locations (1)
Texas
- University of Texas Health Science Center of Houston Dermatology Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 4 |
What the finished NCT00581425 record still lists
NCT00581425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 102-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Imiquimod and Interferon alpha is the first listed.
NCT00581425 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00581425 about?
NCT00581425 is a clinical study titled "Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)". A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
What is the current status of trial NCT00581425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2007-12. Estimated completion is 2011-09.
What conditions does trial NCT00581425 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT00581425?
The interventions under investigation include: Imiquimod and Interferon alpha (BIOLOGICAL).
Who is sponsoring clinical trial NCT00581425?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00581425 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00581425's enrollment target sits among peer trials
49 12th of 24 higher than 13 of 24 other Basal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Basal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RECRUITING · Phase 1
-
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia